Novel human anti-VEGFR2 human antibody for cancer therapy

Dr. Ruei-Min Lu Dr. Ruei-Min Lu

Dr. Ruei-Min Lu

Assistant Research Scientist Antibody R&D core facility in Academia Sinica

发布日期: 2019年10月23日
+ 关注

We discovered and engineered human antibody targeting VEGFR2 from phage display library. It showed anti-tumor activity for prostate cancer and leukemia. The efficacy and safety of this antibody is as well as ramuciramab, the US FDA-approved anti-VEGFR2 Ab. The data was most recently published in Cancer Science in Oct 2019. https://onlinelibrary.wiley.com/doi/full/10.1111/cas.14208

要查看或添加评论，请登录

Dr. Ruei-Min Lu的更多文章

  • Development of therapeutic antibodies for the treatment of diseases
    2020年1月10日

    Development of therapeutic antibodies for the treatment of diseases

    I am pleased to publish the first-author review paper in the Journal of Biomedical Science in Jan 2020. In this review,…

  • 登革疫苗新進展(New development of Dengue vaccine)
    2019年2月1日

    登革疫苗新進展(New development of Dengue vaccine)

    剛剛我看到日本武田製藥(Takeda)研發的四價登革病毒疫苗TAK-003的臨床第3期試驗成功。我不禁好奇它和以前在菲律賓引起軒然大波的 賽諾菲巴斯德公司Dengvaxia有何不同? 可以避免Dengvaxia引起的ADE副作用嗎?…

社区洞察

其他会员也浏览了